Growth Hormone Axis
GHRH analogues and growth-hormone secretagogues acting on the GH/IGF-1 axis.
Tesamorelin: The GHRH Analogue With Real Trial Data Behind It
Tesamorelin is an FDA-approved GHRH analogue with strong trial evidence for reducing visceral fat in HIV-associated lipodystrophy, but off-label use rests on weaker ground.
Evidence gap · The strong evidence comes almost entirely from HIV-associated lipodystrophy; use for general fat loss, non-HIV fatty liver, or anti-ageing is extrapolation with no trial support. Long-term cardiovascular benefit is not established, and the effect reverses after stopping.
Sermorelin: The GHRH Peptide With a Real Clinical Record
A clear, evidence-first look at sermorelin (GHRH 1-29): what it is, what the human trials actually show, and where the anti-ageing hype outruns the data.
Ipamorelin: A Selective GH Secretagogue With Strong Theory and Thin Human Proof
Ipamorelin is a selective ghrelin-receptor agonist that reliably releases growth hormone in animals and humans, but its one human efficacy trial failed and it has no approved use.
IGF-1 LR3: What the Evidence Actually Shows
A clear-eyed look at IGF-1 LR3: solid animal pharmacology, no human trials, and a serious cancer signal that self-experimenters should not ignore.
Hexarelin: The Old-School GH Peptide with a Heart-Focused Twist
A clear, evidence-first look at hexarelin: a potent 1990s growth hormone peptide with intriguing but animal-only cardiac claims and real desensitisation issues.
GHRP-6: The Original GH-Releasing Peptide That Started It All
GHRP-6 is the first GH-releasing hexapeptide and ghrelin-receptor agonist — strong acute GH evidence, robust hunger effect, but largely superseded by cleaner analogues.
GHRP-2 (Pralmorelin): What the Evidence Actually Shows
GHRP-2 reliably triggers a growth hormone pulse and ramps up hunger, but the physique and longevity claims rest on weak, mostly acute data.
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.